Evidence map›Paper›PMID 39252142›Full record

ArticleCardio-oncology (London, England)2024

Outcomes of patients with active cancer after transcatheter aortic valve replacement: an updated meta-analysis.

Nicole Felix, Alleh Nogueira, Pedro E P Carvalho, Thomaz Alexandre Costa, Lucas Tramujas, Giuliano Generoso, Stephanie Feldman, Philippe Garot, Maria do Carmo Andrade Duarte de Farias

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cardio-oncology (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Nicole FelixDivision of Medicine, Federal University of Campina Grande, 795 Juvêncio Arruda Avenue, Campina Grande, Brazil. nicole.santos@estudante.ufcg.edu.br.
Alleh NogueiraDivision of Medicine, Bahiana School of Medicine and Public Health, Salvador, Brazil.
Pedro E P CarvalhoCenter for Coronary Artery Disease, Minneapolis Heart Institute Foundation, Minneapolis, USA.
Thomaz Alexandre CostaDepartment of Medicine, University of Colorado School of Medicine, Aurora, CO, USA.
Lucas TramujasHcor Research Institute, São Paulo, Brazil.
Giuliano GenerosoDivision of Cardiology, Hospital Sírio-Libanês, São Paulo, Brazil.
Stephanie FeldmanDivision of Cardiology, Department of Internal Medicine, Weill Cornell Medicine, New York, NY, USA.
Philippe GarotInstitut Cardiovasculaire Paris Sud (ICPS), Hôpital Jacques Cartier, Ramsay-Santé, Massy, France.
Maria do Carmo Andrade Duarte de FariasDivision of Medicine, Federal University of Campina Grande, 795 Juvêncio Arruda Avenue, Campina Grande, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with active cancer and aortic stenosis may be under-referred for valve interventions due to concerns over a prohibitive risk. However, whether active cancer impacts outcomes after transcatheter aortic valve replacement (TAVR) remains unknown.

methodsWe searched PubMed, Embase, and Cochrane Library in December 2023 for studies comparing the post-TAVR outcomes of patients with versus without active cancer. We pooled odds ratios (OR) and adjusted hazard ratios (aHR) with 95% confidence intervals (CI) applying a random-effects model. Statistical analyses were performed in R version 4.3.2.

resultsWe included nine observational studies analyzing 133,906 patients, of whom 9,792 (7.3%) had active cancer. Compared with patients without cancer, patients with active cancer had higher short- (OR 1.33; 95% CI 1.15-1.55; p < 0.001) and long-term mortality (OR 2.29; 95% CI 1.80-2.91; p < 0.001) rates, not driven by cardiovascular mortality (OR 1.30; 95% CI 0.70-2.40; p = 0.40), and higher major bleeding rates (OR 1.66; 95% CI 1.15-2.42; p = 0.008). The higher mortality rate was sustained in an adjusted analysis (aHR 1.77; 95% CI 1.34-2.35; p < 0.001). There was no significant difference in cardiac, renal, and cerebral complications at a follow-up ranging from 180 days to 10 years.

conclusionPatients with active cancer undergoing TAVR had higher non-cardiovascular mortality and bleeding rates, with comparable incidences of other complications. This highlights the need for a shared decision and appropriate patient selection considering cancer type, staging, bleeding risk, and optimal timing for intervention.

Indexed as

Aortic valve stenosisCardio-oncologyMeta-analysisNeoplasmsTranscatheter aortic valve replacement

Identifiers

PMID39252142
PMCPMC11386488

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.